TY - JOUR
T1 - Control conditions for randomised trials of behavioural interventions in psychiatry
T2 - a decision framework
AU - Gold, Stefan M.
AU - Enck, Paul
AU - Hasselmann, Helge
AU - Friede, Tim
AU - Hegerl, Ulrich
AU - Mohr, David C.
AU - Otte, Christian
N1 - Funding Information:
SMG is supported by a Heisenberg Professorship from the Deutsche Forschungsgemeinschaft ( GO1357/5-2 ). DCM is supported by grants R01 MH100482, R01 MH109496, and R01 MH095753 from the US National Institute of Mental Health . HH (NeuroCure PhD fellow) and CO (NeuroCure principal investigator) received support from the Deutsch Forschungsgemeinschaft (EXC257). The funding sources had no role in any aspect pertinent to the study.
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/9
Y1 - 2017/9
N2 - In psychiatry, comparative analyses of therapeutic options and the aggregation of data from clinical trials across different therapeutic approaches play an important role in clinical decision making, treatment guidelines, and health policy. This approach assumes that trials of pharmacological and behavioural therapies generally produce the same level of evidence when properly designed. However, trial design for behavioural interventions has some unique characteristics and control groups vary widely, which influence the effects observed in any given trial. In this Personal View, we review various control conditions typically used in psychiatry, outline their effect on the internal validity and expected effect size of a trial, and propose a decision framework for choosing a control condition depending on the risk to the patient population and the stage of development of the therapeutic intervention. We argue that the choice of control group and its justification need to be taken into consideration when comparing behavioural and pharmacological therapies.
AB - In psychiatry, comparative analyses of therapeutic options and the aggregation of data from clinical trials across different therapeutic approaches play an important role in clinical decision making, treatment guidelines, and health policy. This approach assumes that trials of pharmacological and behavioural therapies generally produce the same level of evidence when properly designed. However, trial design for behavioural interventions has some unique characteristics and control groups vary widely, which influence the effects observed in any given trial. In this Personal View, we review various control conditions typically used in psychiatry, outline their effect on the internal validity and expected effect size of a trial, and propose a decision framework for choosing a control condition depending on the risk to the patient population and the stage of development of the therapeutic intervention. We argue that the choice of control group and its justification need to be taken into consideration when comparing behavioural and pharmacological therapies.
UR - http://www.scopus.com/inward/record.url?scp=85017148397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017148397&partnerID=8YFLogxK
U2 - 10.1016/S2215-0366(17)30153-0
DO - 10.1016/S2215-0366(17)30153-0
M3 - Review article
C2 - 28396067
AN - SCOPUS:85017148397
SN - 2215-0366
VL - 4
SP - 725
EP - 732
JO - The Lancet Psychiatry
JF - The Lancet Psychiatry
IS - 9
ER -